Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-01-01

Clinical Trial Update: To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy. [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 study to evaluate the long-term safety of pregabalin in patients with refractory partial epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pregabalin (Pregabalin)

Snippet

Sponsor: Pfizer | Conditions: Epilepsy, Partial | Phase 2 | Status: COMPLETED